The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Author:
Funder
NHMRC
Victorian Government, Australia
Publisher
Elsevier BV
Subject
Cancer Research
Reference142 articles.
1. Immunosuppressive networks in the tumour environment and their therapeutic relevance;Zou;Nat. Rev. Cancer,2005
2. Cancer immunoediting: from immunosurveillance to tumor escape;Dunn;Nat. Immunol.,2002
3. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer;Grivennikov;Cancer Cell,2009
4. The role of IL-6 and STAT3 in inflammation and cancer;Hodge;Eur. J. Cancer,2005
5. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway;Heinrich;Biochem. J.,1998
Cited by 157 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement;ACS Omega;2024-08-28
2. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines;Cell Reports;2024-08
3. Inhibition of STAT3: A promising approach to enhancing the efficacy of chemotherapy in medulloblastoma;Translational Oncology;2024-08
4. LINC00518: a key player in tumor progression and clinical outcomes;Frontiers in Immunology;2024-07-23
5. Citicoline modulates inflammatory signaling pathways in the spleen of rats exposed to gamma-radiation;Immunopharmacology and Immunotoxicology;2024-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3